| AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases. Co.'s full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. Rather than advancing its own clinical pipeline of drug candidates, Co. forges partnerships with drug developers of all sizes, from pharmaceutical to small biotechnology companies. In a collaboration with Eli Lilly and Company, Co. has applied its technology stack to co-develop LY-CoV555, a potential antibody therapy to treat and prevent COVID-19. We show 5 historical shares outstanding datapoints in our coverage of ABCL's shares outstanding history.|
Understanding the changing numbers of ABCL shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABCL versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABCL by allowing them to research ABCL shares outstanding history
as well as any other stock in our coverage universe.